WallStreetZen

NASDAQ: AGRX
Agile Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for AGRX

Based on 2 analysts offering 12 month price targets for Agile Therapeutics Inc.
Min Forecast
$2.50+292.46%
Avg Forecast
$3.75+488.7%
Max Forecast
$5.00+684.93%

Should I buy or sell AGRX stock?

Based on 2 analysts offering ratings for Agile Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

AGRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 2%
2
BuyMaintains$2.50+292.46%2021-11-03
RBC Capital
Bottom 18%
18
BuyMaintains$5.00+684.93%2021-07-27
Anonymous
HC Wainwright & Co.
BuyMaintains$7.00+998.90%2020-12-08

1 of 1

Forecast return on equity

Is AGRX forecast to generate an efficient return?
Company
45.47%
Industry
91.05%
Market
37.5%
AGRX's Return on Equity is forecast to be high in 3 years (45.47%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is AGRX forecast to generate an efficient return on assets?
Company
13.24%
Industry
76.61%
AGRX is forecast to generate lower Return on Assets (13.24%) than the US Drug Manufacturers - Specialty & Generic industry average (76.61%)
Forecast

AGRX earnings per share forecast

What is AGRX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.78+0%
Avg 2 year Forecast
-$0.58-25.64%
Avg 3 year Forecast
-$0.27-65.38%

AGRX revenue forecast

What is AGRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$4.4M+30.9%
Avg 2 year Forecast
$22.6M+577.05%
Avg 3 year Forecast
$73.2M+2,092.39%
AGRX's revenue is forecast to grow at an exceptional rate of 170.02% per year
Forecast

AGRX revenue growth forecast

How is AGRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
170.02%
Industry
24.29%
Market
10.08%
AGRX's revenues are forecast to grow faster (170.02% per year) than the US Drug Manufacturers - Specialty & Generic industry average (24.29%)
Forecast
AGRX's revenues are forecast to grow faster (170.02% per year) than the US market average (10.08%)
Forecast

Agile Therapeutics Stock Forecast FAQ

Is Agile Therapeutics Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AGRX) stock is to Buy AGRX stock.

Out of 2 analysts, 0 (0%) are recommending AGRX as a Strong Buy, 2 (100%) are recommending AGRX as a Buy, 0 (0%) are recommending AGRX as a Hold, 0 (0%) are recommending AGRX as a Sell, and 0 (0%) are recommending AGRX as a Strong Sell.

What is AGRX's earnings growth forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 27.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Agile Therapeutics's earnings in 2021 is -$69,157,000.On average, 3 Wall Street analysts forecast AGRX's earnings for 2021 to be $-94,688,906, with the lowest AGRX earnings forecast at $-105,614,549, and the highest AGRX earnings forecast at $-83,763,263. On average, 3 Wall Street analysts forecast AGRX's earnings for 2022 to be $-70,409,699, with the lowest AGRX earnings forecast at $-112,898,311, and the highest AGRX earnings forecast at $-47,344,453.

In 2023, AGRX is forecast to generate $-32,776,929 in earnings, with the lowest earnings forecast at $-37,632,770 and the highest earnings forecast at $-27,921,088.

What is AGRX's revenue growth forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual revenue growth rate of 170.02% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 24.29%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Agile Therapeutics's revenue in 2021 is $3,337,000.On average, 3 Wall Street analysts forecast AGRX's revenue for 2021 to be $530,257,872, with the lowest AGRX revenue forecast at $522,002,942, and the highest AGRX revenue forecast at $534,870,921. On average, 3 Wall Street analysts forecast AGRX's revenue for 2022 to be $2,742,700,574, with the lowest AGRX revenue forecast at $2,501,972,240, and the highest AGRX revenue forecast at $3,107,738,445.

In 2023, AGRX is forecast to generate $8,881,333,774 in revenue, with the lowest revenue forecast at $5,623,064,249 and the highest revenue forecast at $12,139,603,300.

What is AGRX's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: AGRX) forecast ROA is 13.24%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 76.61%.

What is AGRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AGRX price target, the average AGRX price target is $3.75, with the highest AGRX stock price forecast at $5.00 and the lowest AGRX stock price forecast at $2.50.

On average, Wall Street analysts predict that Agile Therapeutics's share price could stay at $3.75 by Nov 3, 2022. The average Agile Therapeutics stock price prediction forecasts a potential downside of N/A from the current AGRX share price of $0.64.

What is AGRX's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's current Earnings Per Share (EPS) is -$0.78. On average, analysts forecast that AGRX's EPS will be $-0.78 for 2021, with the lowest EPS forecast at $-0.87, and the highest EPS forecast at $-0.69. On average, analysts forecast that AGRX's EPS will be $-0.58 for 2022, with the lowest EPS forecast at $-0.93, and the highest EPS forecast at $-0.39. In 2023, AGRX's EPS is forecast to hit $-0.27 (min: $-0.31, max: $-0.23).

What is AGRX's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: AGRX) forecast ROE is 45.47%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.